Sep 08, 2021 7:00am EDT Immunocore Announces UK’s Medicines and Healthcare Products Regulatory Agency (MHRA) Accepts Marketing Authorization Application for Tebentafusp in Metastatic Uveal Melanoma
Aug 24, 2021 7:00am EDT Immunocore Announces that U.S. Food and Drug Administration and European Medicines Agency accept Biologics License Application and Marketing Authorization Application for Tebentafusp in Metastatic Uveal Melanoma
Aug 11, 2021 7:00am EDT Immunocore Reports Second Quarter 2021 Financial Results and Provides Business Update
Jun 04, 2021 9:05am EDT Immunocore presents clinical data further characterizing the overall survival benefit of tebentafusp in metastatic uveal melanoma at the 2021 American Society of Clinical Oncology (ASCO) Annual Meeting
May 18, 2021 4:10pm EDT Immunocore announces dosing of first patient with ImmTAV® bispecific molecule for chronic Hepatitis B
Apr 28, 2021 4:30pm EDT Immunocore Announces Upcoming Presentations at the 2021 American Society of Clinical Oncology (ASCO) Annual Meeting
Apr 12, 2021 4:30pm EDT Immunocore presents phase 3 data comparing tebentafusp with investigator’s choice in the clinical trial plenary session at the American Association for Cancer Research 2021 Annual Meeting